EGFR T790M+ group did not encompass any mutations on genes KRAS, MET, ALK and FGFR1 (Figure 3A), while all these genes have been suggested resulting in poor responses to EGFR TKIs in NSCLC patients [30–32]. Here, ALK is linked to non-small cell lung carcinoma.